Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.59 | N/A | -25.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.59 | N/A | -25.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions impacting performance. They remain committed to their long-term strategy.
Management acknowledged challenges in the current market environment.
They emphasized a focus on long-term goals despite short-term setbacks.
Ionis Pharmaceuticals reported a loss that was worse than expected, leading to a 4.44% drop in stock price. Investors may be concerned about the company's ability to navigate current market challenges. The lack of revenue details and guidance adds uncertainty to future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Lantheus Holdings, Inc.